Barclays
ANIP icon

Barclays’s ANI Pharmaceuticals ANIP Stock Holding History

Barclays’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,000
Closed -$90K – 6986
2018
Q4 		$90K Sell
2,000
-200
-9% -$10.5K ﹤0.01% 5109
2018
Q3 		$124K Buy
2,200
+2,000
+1,000% +$122K ﹤0.01% 5368
2018
Q2 		$13K Sell
200
-400
-67% -$25K ﹤0.01% 6398
2018
Q1 		$35K Sell
600
-100
-14% -$6.35K ﹤0.01% 6141
2017
Q4 		$45K Buy
700
+600
+600% +$37.3K ﹤0.01% 5815
2017
Q3 		$5K Hold
100
– – ﹤0.01% 6395
2017
Q2 		$5K Sell
100
-1,000
-91% -$48.2K ﹤0.01% 6220
2017
Q1 		$54K Hold
1,100
– – ﹤0.01% 5291
2016
Q4 		$67K Buy
+1,100
New +$67.3K ﹤0.01% 4983
2015
Q2 		– Sell
-95,800
Closed -$5.94M – 6996
2015
Q1 		$5.94M Buy
+95,800
New +$5.83M 0.01% 1429
2014
Q1 		– Sell
-336
Closed -$7K – 7556
2013
Q4 		$7K Hold
336
– – ﹤0.01% 7085
2013
Q3 		$3K Sell
336
-23
-6% -$166 ﹤0.01% 7095
2013
Q2 		$2K Buy
+359
New +$2.51K ﹤0.01% 7511

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Barclays's ANIP Position: Q1 2026 in Review

Barclays reduced its ANI Pharmaceuticals (ANIP) stake by 18% in Q1 2026, selling an estimated $1.12M and leaving 67,447 shares worth $5.19M. The position accounts for ﹤0.01% of the portfolio, ranked #1798.

Barclays first reported a position in ANIP in Q2 2013 and has held it in 52 quarters since. The position peaked at $12M in Q2 2025. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Barclays held 67,447 shares of ANI Pharmaceuticals worth $5.19M as of Q1 2026.
  • Barclays sold 14,343 ANI Pharmaceuticals shares in Q1 2026, an estimated $1.12M.
  • ANI Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1798 holding.
  • Barclays first reported a position in ANI Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Barclays's ANI Pharmaceuticals position peaked at $12M in Q2 2025.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.